Clinical Research Protocols In Ovarian Cancer

Compiled by Margaret Gross-King, RN, MS, OCN
Clinical Research Manager, H. Lee Moffitt Cancer Center & Research Institute

(Editor's note: The following listing includes studies being performed only by cooperative groups in the United States. For studies in other gynecologic neoplasms or for foreign and single-institution studies, please contact PDQ.)

**GOG-93 Phase III Randomized Evaluation of Adjuvant Intraperitoneal 32-P Following Negative Second-Look Laparotomy in Patients With Stage III Epithelial Ovarian Carcinoma (Summary last modified 11/93).**

**GOG-157 Phase III Randomized Study of CBDCA/TAX Administered for 3 vs 6 Courses for Selected Stages IA-C and Stages IIA-C Ovarian Epithelial Cancer (Summary last modified 10/95).**

**SWOG-9249 Phase III Randomized Study of High-Dose CBDCA/CTX With G-CSF Followed by Standard-Dose TAX vs High-Dose TAX With G-CSF for Nonpalpable Suboptimal Stage III Ovarian Epithelial Carcinoma (Summary last modified 09/95).**

**GOG-158 Phase III Randomized Study of Platinum Compound and TAX in Optimal Stage III Ovarian Epithelial Cancer: CDDP and TAX (24-Hour Infusions) vs CBD and TAX (3-Hour Infusion) (Summary last modified 10/95).**

**GOG-152 Phase III Randomized Study of TAX/CDDP Alone vs TAX/CDDP With Interval Secondary Cytoreductive Surgery for Suboptimally Resected Stage III and Selected Stage IV Ovarian Epithelial Carcinoma (Summary last modified 09/95).**
Chairman: Peter Graham Rose, Case Western Reserve University, Cleveland, Ohio. Lead Organization: Gynecological Oncology Group. Acceptable age range: any age.

**GOG-114 Phase III Randomized Trial of Intravenous CDDP/CTX vs Intravenous CDDP/TAX vs Intravenous High-Dose CBDCA Followed by Intravenous TAX/Intraperitoneal CDDP in Patients With Optimal Stage III Ovarian Epithelial Cancer (Summary last modified 10/94).**

**GOG-90 Phase II Combination Chemotherapy With BEP (CDDP/VP-16/BLEO) as Induction Followed by VAC (VCR/DACT/CTX) as Consolidation in Patients With Incompletely Resected Malignant Ovarian Germ Cell Tumors (Summary last modified 10/95).**
Chairman: Stephen D. Williams, Indiana University Medical Center, Indianapolis, Ind. Lead Organization: Gynecological Oncology Group. Acceptable age range: any age.

**SWOG-9106 Phase II Randomized Study of CTX/DHAD/CBDCA vs TSPA/CTX/CDDP, Each With Autologous Bone Marrow Support, in Patients With Recurrent or Persistent Ovarian Cancer (Summary last modified 08/94).**
Chairman: Patrick J. Stiff, Stritch School of Medicine, Maywood, Ill. Lead Organization: Southwest Oncology Group. Acceptable age range: 65 and under.

**NCI-95-C-0056A Phase II Study of Continuous-Infusion Aminocamptothecin for Advanced Epithelial Ovarian Cancer Recurrent After Paclitaxel and Either Cisplatin or Carboplatin (Summary last modified 06/95) (NCI-95-C-0056A).**

**NCI-95-C-0055B Phase II Study of CTX/TAX/CDDP With G-CSF in Newly Diagnosed Stage IIC/III/IV Ovarian Epithelial Cancer (Summary last modified 07/95).**

**SWOG-9326 Phase II Study of HMM for Consolidation of Clinical Complete Response in Patients With Stage III Ovarian Epithelial Cancer (Summary last modified 02/95).**

**GOG-9302 Phase II Study of Laparoscopic Staging in Patients With Incompletely Staged Ovarian Cancer (Summary last modified 10/94).**

**SWOG-9324 Phase II Study of Vinorelbine for Relapsed or Refractory Epithelial Ovarian Cancer (Summary last modified 07/95).**

**GOG-9202 Phase I Pilot Study of TAX/CBDCA/G-CSF With and Without IL-6 for Untreated Suboptimal Stage III/IV Ovarian Epithelial or Primary Peritoneal Carcinoma (Summary last modified 06/95).**
GOG-9203 Phase I Study of TAX/VP-16 With and Without G-CSF in Patients With Refractory Ovarian Cancer (Summary last modified 08/94).
Chairman: Gini Fleming, University of Chicago Hospital, Chicago, Ill. Lead Organization: Gynecological Oncology Group. Acceptable age range: 18 and over.

GOG-9201 Chairman: Maurie Markman, Cleveland Clinic Foundation Hospital, Cleveland, Ohio. Lead Organization: Gynecological Oncology Group. Acceptable age range: 18 and over.

Legend for Abbreviations:
GOG = Gynecologic Oncology Group
NCI = National Cancer Institute
SWOG = Southwest Oncology Group